Galecto, Inc.
DMRA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 85.0% and free cash flow fell 877.5%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow DMRA
Galecto, Inc. (DMRA) Piotroski F-score
Piotroski F-score, annual
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|
How the score is made up
There are no annual figures to work it out from.
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| TSHA Taysha Gene Therapies, Inc. compare | 4 |
| LBRX LB Pharmaceuticals Inc compare | — |
| DMRA Galecto, Inc. | — |
| VOR Vor Biopharma Inc. compare | — |
| BCAX Bicara Therapeutics Inc. compare | — |
| DRTS Alpha Tau Medical Ltd. compare | — |
| SNDX Syndax Pharmaceuticals, Inc. compare | — |
| NBTX Nanobiotix S.A. - Sponsored ADR compare | — |
| REPL Replimune Group, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover